XYL Stock Defies Yearly Trend, Soars Today

This morning we watched Xylem rise 2.1% to a price of $96.29 per share. The large-cap Fluid Controls company is now trading -19.08% below its average target price of $119.0. Analysts have set target prices ranging from $101.0 to $135.0 per share for Xylem, and have given the stock an average rating of buy.

Xylem's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.1%. The stock's short ratio is 2.67. The company's insiders own 0.29% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 76.7%. In conclusion, we believe there is mixed market sentiment regarding Xylem.

Institutions Invested in Xylem

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 12% 27,815,182 $2,678,323,900
2023-06-30 Blackrock Inc. 11% 25,741,159 $2,478,616,223
2023-06-30 State Street Corporation 4% 9,868,835 $950,270,131
2023-06-30 Aristotle Capital Management, LLC 4% 9,510,630 $915,778,571
2023-06-30 Pictet Asset Management SA 3% 6,997,852 $673,823,175
2023-06-30 Geode Capital Management, LLC 2% 5,021,113 $483,482,975
2023-06-30 Amundi 2% 5,015,829 $482,974,179
2023-06-30 Morgan Stanley 2% 4,061,994 $391,129,405
2023-06-30 Invesco Ltd. 1% 3,096,719 $298,183,075
2023-06-30 Bank of America Corporation 1% 3,081,631 $296,730,251
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.